18F-FDG PET has limited diagnostic applications in malignant melanoma (MM). 18F-N-(2-
(diethylamino) ethyl)-5-(2-(2-(2-fluoroethoxy) ethoxy) ethoxy) picolinamide (18F-PFPN) is a …

Recently the potential of whole-body positron emission tomography scanning using 18 F-
fluorodeoxyglucose (FDG PET) has led to renewed interest in the use of functional imaging …

N-(2-(diethylamino)-ethyl)-18F-5-fluoropicolinamide (18F-P3BZA) is a radiotracer that
demonstrates high binding selectivity and affinity in melanoma. The aim of the present study …

Purpose Positron emission tomography (PET) using [18F]-PFPN, a melanin-targeted
imaging tracer, has excellent diagnostic performance in patients with melanoma. This study …

Purpose Radiolabelled benzamides are attractive candidates for targeting melanoma
because they bind to melanin and exhibit high tumour uptake and retention. 18 F-5-Fluoro-N …

Purpose The purpose of this retrospective, blinded study was to evaluate the additional
value of [18 F] FDG PET/CT in comparison with PET alone and with side-by-side PET and …

Malignant melanoma is an aggressive and serious form of skin cancer, with prognosis and
treatment outcome depending heavily on the clinical stage of the disease at the time of …

Purpose To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[18
F] fluoro-D-glucose ([18 F] FDG) positron emission tomography (PET)/magnetic resonance …

Although 18F-5-fluoro-N-(2-[diethylamino] ethyl) picolinamide (18F-5-FPN) is considered a
promising radiopharmaceutical for PET imaging of melanoma, it accumulates at high …

Abstract Introduction 18 F-5-fluoro-N-(2-(Diethylamino) ethyl) picolinamide (18 F-5-FPN) is a
new positron-emission tomography (PET) radiopharmaceutical with potential for the …